DSM Pharmaceuticals Appoints Business Unit Director - - BioPharm International

ADVERTISEMENT

DSM Pharmaceuticals Appoints Business Unit Director



DSM Pharmaceuticals has appointed Manja Bouman PhD as president and business unit director of its biopharm businesses at DSM Pharmaceutical Products. Bouman will head the DSM Biologics/BioSolutions businesses within the DSM Pharmaceutical Products business group of Royal DSM. Bouman will report to Lukas Utiger, president and CEO of DSM Pharmaceutical Products, as a member of the management team.

Bouman has a PhD in biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences and has held postdoctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In that role, Bouman was responsible for new business development and licensing & technology moving to Kiadis Pharma B.V. as CEO in 2004. Bouman was most recently CEO of Regenesance, a company that focuses on the development of monoclonal antibodies that inhibit MAC formation for treatment of chronic and acute neurological disorders.

Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large-and small-molecule API’s for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.

Source: DSM Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here